Kumar A, Gautam V, Sandhu A, Rawat K, Sharma A, Saha L
World J Gastrointest Surg. 2023; 15(4):495-519.
PMID: 37206081
PMC: 10190721.
DOI: 10.4240/wjgs.v15.i4.495.
Carlsson G, Koumarianou A, Guren T, Haux J, Katsaounis P, Kentepozidis N
ESMO Open. 2022; 7(5):100589.
PMID: 36183444
PMC: 9588906.
DOI: 10.1016/j.esmoop.2022.100589.
Gustavsson B, Carlsson G, Swartling T, Kurlberg G, Derwinger K, Bjorkqvist H
Invest New Drugs. 2015; 33(5):1078-85.
PMID: 26189513
PMC: 4768212.
DOI: 10.1007/s10637-015-0272-0.
Kline C, El-Deiry W
Pharmaceuticals (Basel). 2013; 6(8):988-1038.
PMID: 24276379
PMC: 3817731.
DOI: 10.3390/ph6080988.
Fanciullino R, Giacometti S, Aubert C, Fina F, Martin P, Piccerelle P
Pharm Res. 2005; 22(12):2051-7.
PMID: 16222443
DOI: 10.1007/s11095-005-8355-9.
A phase II pilot study of high-dose 24-hour continuous infusion of 5-FU and leucovorin and low-dose PALA for patients with colorectal cancer: a Southwest Oncology Group study.
Whitehead R, Benedetti J, Abbruzzese J, Ardalan B, Williamson S, Gaynor E
Invest New Drugs. 2004; 22(4):467-73.
PMID: 15292717
DOI: 10.1023/B:DRUG.0000036689.28596.c6.
A phase II study of high-dose 24 hour continuous infusion 5-FU and leucovorin and low-dose PALA for patients with advanced pancreatic adenocarcinoma: a Southwest Oncology Group Study.
Whitehead R, Benedetti J, Abbruzzese J, Ardalan B, Goodwin J, Balcerzak S
Invest New Drugs. 2004; 22(3):335-41.
PMID: 15122082
DOI: 10.1023/B:DRUG.0000026261.76197.54.
Both gene expression for orotate phosphoribosyltransferase and its ratio to dihydropyrimidine dehydrogenase influence outcome following fluoropyrimidine-based chemotherapy for metastatic colorectal cancer.
Ichikawa W, Uetake H, Shirota Y, Yamada H, Takahashi T, Nihei Z
Br J Cancer. 2003; 89(8):1486-92.
PMID: 14562021
PMC: 2394351.
DOI: 10.1038/sj.bjc.6601335.
Dihydropyrimidine dehydrogenase (DPD) activity in gastric cancer tissue and effect of DPD inhibitory fluoropyrimidines.
Usuki H, Ishimura K, Yachida S, Hagiike M, Okano K, Izuishi K
Gastric Cancer. 2003; 6 Suppl 1:66-70.
PMID: 12775023
DOI: 10.1007/s10120-003-0225-8.
Phase I clinical trial of 5-fluoro-pyrimidinone (5FP), an oral prodrug of 5-fluorouracil (5FU).
LoRusso P, Prakash S, Wozniak A, Flaherty L, Zalupski M, Shields A
Invest New Drugs. 2002; 20(1):63-71.
PMID: 12003195
DOI: 10.1023/a:1014430216434.
Resection of locally advanced pancreatic cancer after downstaging with continuous-infusion 5-fluorouracil, mitomycin-C, leucovorin, and dipyridamole.
Todd K, Gloor B, LANE J, Isacoff W, Reber H
J Gastrointest Surg. 1998; 2(2):159-66.
PMID: 9834413
DOI: 10.1016/s1091-255x(98)80008-5.
Experimental studies on potentiation of the antitumor activity of 5-fluorouracil with 3'-azido-3'-deoxythymidine for the gastric cancer cell line MKN28 in vivo.
Yasuda C, Kato M, Kuroda D, Ohyanagi H
Jpn J Cancer Res. 1997; 88(1):97-102.
PMID: 9045902
PMC: 5921241.
DOI: 10.1111/j.1349-7006.1997.tb00307.x.
How to optimize the effect of 5-fluorouracil modulated therapy in advanced colorectal cancer.
Ragnhammar P, Blomgren H
Med Oncol. 1995; 12(3):187-201.
PMID: 8852401
DOI: 10.1007/BF01571196.
Intraarterial hepatic chemotherapy with fluorouracil, fluorodeoxyuridine, mitomycin C, cisplatin or methotrexate as single-agent anticancer drugs for a transplanted experimental liver tumor in rats.
Kurth S, Bulian D, Kreft B, Riemenschneider T
J Cancer Res Clin Oncol. 1996; 122(7):421-6.
PMID: 8690753
DOI: 10.1007/BF01212882.
The modulation by L-leucovorin of 5-fluorouracil antitumor activity on human colon carcinoma cells in vitro and in vivo.
Kase S, Kubota T, Watanabe M, Takahara T, Takeuchi T, Yamaguchi H
Surg Today. 1993; 23(7):615-20.
PMID: 8369613
DOI: 10.1007/BF00311910.
Pharmacokinetics of rac-leucovorin vs [S]-leucovorin in patients with advanced gastrointestinal cancer.
Mader R, Steger G, Rizovski B, Sieder A, Locker G, Gnant M
Br J Clin Pharmacol. 1994; 37(3):243-8.
PMID: 8198932
PMC: 1364754.
DOI: 10.1111/j.1365-2125.1994.tb04270.x.
Comparative cytotoxicity of folate-based inhibitors of thymidylate synthase and 5-fluorouracil +/- leucovorin in MGH-U1 cells.
Erlichman C, Mitrovski B
Cancer Chemother Pharmacol. 1994; 34(1):51-6.
PMID: 8174202
DOI: 10.1007/BF00686111.
Double modulation of 5-fluorouracil by high-dose leucovorin and interferon alpha 2b in advanced colorectal cancer: a phase I and a phase II study of weekly administration.
Steger G, Mader R, Djavanmard M, Gnant M, Locker G, Marosi C
J Cancer Res Clin Oncol. 1994; 120(5):314-8.
PMID: 8126062
DOI: 10.1007/BF01236390.
Phase I and pharmacokinetic evaluation of floxuridine/leucovorin given on the Roswell Park weekly regimen.
Creaven P, Rustum Y, Petrelli N, Meropol N, Raghavan D, Rodriguez-Bigas M
Cancer Chemother Pharmacol. 1994; 34(3):261-5.
PMID: 8004761
DOI: 10.1007/BF00685087.
The pharmacokinetics of reduced folates after intraperitoneal and intravenous administration of racemic [6S,R]-folinic acid.
Sips J, van Tellingen O, Nooijen W, Rodenhuis S, Ten Bokkel Huinink W, Beijnen J
Cancer Chemother Pharmacol. 1994; 35(2):144-8.
PMID: 7987991
DOI: 10.1007/BF00686637.
